Hans Lee, MD
Internal Medicine · Houston, TXNPI 1144470758
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $273,665 of the $326,817 with a category attached, or 83.7%. 38 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 26.6% of the total. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 279 payments — averaging $1171.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$87K
- Sanofi$43K
- GSK$38K
- Bristol Myers Squibb$27K
- E.r. Squibb & Sons, L.L.C.$25K
- Johnson & Johnson$23K
- plus $83K from 32 others
Across 476 payments — averaging $23,954 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$4.6M
- Takeda Pharmaceuticals U.S.A., Inc.$3.5M
- Amgen$1.1M
- GSK$798K
- Janssen Research & Development, LLC$650K
- Menarini Silicon Biosystems, Inc.$282K
- plus $426K from 4 others
What the payments were for
- Consulting fees$273,66584%
- Speaking & faculty fees$15,0465%
- Travel & lodging$30,3229%
- Food & beverage$7,7842%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $87,056 |
| Sanofi | 15 | $43,100 |
| GSK | 27 | $38,011 |
| Bristol Myers Squibb | 21 | $27,233 |
| E.r. Squibb & Sons, L.L.C. | 14 | $25,264 |
| Johnson & Johnson(2 entities) | 27 | $23,122 |
| Regeneron | 32 | $23,099 |
| Janssen Scientific Affairs, LLC | 17 | $17,260 |
| Pfizer | 10 | $14,555 |
| Menarini Silicon Biosystems, Inc. | 3 | $7,078 |
| AbbVie | 9 | $6,422 |
| AstraZeneca(2 entities) | 7 | $3,755 |
| Adaptive Biotechnologies Corporation | 2 | $2,539 |
| Karyopharm Therapeutics Inc. | 3 | $2,523 |
| Genentech, Inc. | 2 | $2,200 |
| Janssen Global Services, LLC | 4 | $1,871 |
| Legend Biotech USA Inc. | 8 | $586 |
| Regeneron Healthcare Solutions, Inc. | 7 | $284 |
| Amgen | 3 | $210 |
| Daiichi Sankyo Inc. | 3 | $76 |
| Modernatx, Inc. | 1 | $67 |
| Astrazeneca UK Limited | 1 | $52 |
| F. Hoffmann-la Roche AG | 1 | $50 |
| Beone Medicines USA, Inc. | 2 | $46 |
| EMD Serono, Inc. | 2 | $40 |
| Novocure Inc. | 2 | $35 |
| Genentech USA, Inc. | 2 | $34 |
| Caris MPI, Inc. | 2 | $31 |
| Genmab U.S., Inc. | 1 | $25 |
| Avyxa Pharma, LLC | 1 | $25 |
| Eisai Inc. | 1 | $24 |
| Merck | 1 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Seagen Inc. | 1 | $21 |
| Exelixis Inc. | 1 | $21 |
| Invivyd Inc | 1 | $20 |
| Celltrion USA Inc. | 1 | $20 |
| Tempus AI, Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$326,817 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 161 | $2,888,800 |
| Lenalidomide | 136 | $2,070,004 |
| PomalystPomalidomide | 87 | $1,918,861 |
| NinlaroIxazomib Citrate | 11 | $158,219 |
| VenclextaVenetoclax | 12 | $130,243 |
| ValacyclovirValacyclovir Hcl | 77 | $2,979 |
| CholestyramineCholestyramine (With Sugar) | 18 | $961 |
| Dexamethasone | 36 | $399 |
| Pantoprazole Sodium | 33 | $279 |
| Ondansetron Hcl | 27 | $95 |
| Levofloxacin | 11 | $51 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 20 | $35 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $27,233 | $2,888,800161 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $25,264 | $1,918,86187 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $87,056 | $158,21911 claims |
| AbbVieVenclexta | $6,422 | $130,24312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Houston
- Hussein TawbiHouston$365K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
- Krina PatelHouston$255K
- Nicholas ShortHouston$247K
- Naveen PemmarajuHouston$230K
- Mariana Chavez MacgregorHouston$188K
- Shumei KatoHouston$180K
- Sukhdeep BasraHouston$168K
- Paolo StratiHouston$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.